1. Home
  2. BBWI vs GRFS Comparison

BBWI vs GRFS Comparison

Compare BBWI & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBWI
  • GRFS
  • Stock Information
  • Founded
  • BBWI 1963
  • GRFS 1940
  • Country
  • BBWI United States
  • GRFS Spain
  • Employees
  • BBWI N/A
  • GRFS N/A
  • Industry
  • BBWI Clothing/Shoe/Accessory Stores
  • GRFS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBWI Consumer Discretionary
  • GRFS Health Care
  • Exchange
  • BBWI Nasdaq
  • GRFS Nasdaq
  • Market Cap
  • BBWI 6.1B
  • GRFS 6.2B
  • IPO Year
  • BBWI N/A
  • GRFS 2006
  • Fundamental
  • Price
  • BBWI $33.00
  • GRFS $9.82
  • Analyst Decision
  • BBWI Buy
  • GRFS Hold
  • Analyst Count
  • BBWI 18
  • GRFS 1
  • Target Price
  • BBWI $41.76
  • GRFS $10.30
  • AVG Volume (30 Days)
  • BBWI 5.8M
  • GRFS 803.7K
  • Earning Date
  • BBWI 08-27-2025
  • GRFS 01-01-0001
  • Dividend Yield
  • BBWI 2.44%
  • GRFS N/A
  • EPS Growth
  • BBWI N/A
  • GRFS N/A
  • EPS
  • BBWI 3.74
  • GRFS 0.31
  • Revenue
  • BBWI $7,347,000,000.00
  • GRFS $7,968,532,207.00
  • Revenue This Year
  • BBWI $4.27
  • GRFS $7.14
  • Revenue Next Year
  • BBWI $2.73
  • GRFS $7.16
  • P/E Ratio
  • BBWI $8.77
  • GRFS $39.36
  • Revenue Growth
  • BBWI N/A
  • GRFS 10.76
  • 52 Week Low
  • BBWI $24.94
  • GRFS $6.19
  • 52 Week High
  • BBWI $41.87
  • GRFS $9.96
  • Technical
  • Relative Strength Index (RSI)
  • BBWI 63.83
  • GRFS 72.22
  • Support Level
  • BBWI $32.46
  • GRFS $8.84
  • Resistance Level
  • BBWI $33.96
  • GRFS $9.19
  • Average True Range (ATR)
  • BBWI 1.04
  • GRFS 0.23
  • MACD
  • BBWI 0.46
  • GRFS 0.06
  • Stochastic Oscillator
  • BBWI 82.42
  • GRFS 95.66

About BBWI Bath & Body Works Inc.

Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 5% of sales from international markets in fiscal 2024. For fiscal 2024, 76% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,800 retail stores), similar to 2023 levels, as consumer shopping patterns remained to normal. Future growth is expected from store reformatting, digital and international channels, as well as adjacent category expansions like hair and laundry.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: